ALK and breast carcinoma: Within this group, only four recommendations were of tier 1 clinical evidence level (1x PIK3CA/KRAS-mutated breast cancer, 1x MET-mutated kidney cancer, 1x ALK fusion-positive NSCLC, and 1x BRCA2-mutated pancreas cancer).